Lyka Labs Ltd
Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages[1]
- Market Cap ₹ 443 Cr.
- Current Price ₹ 124
- High / Low ₹ 144 / 97.9
- Stock P/E
- Book Value ₹ 17.9
- Dividend Yield 0.00 %
- ROCE 3.95 %
- ROE -6.61 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Promoter holding has increased by 3.29% over last quarter.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 9.45% over past five years.
- Company might be capitalizing the interest cost
- Debtor days have increased from 67.4 to 88.6 days.
- Working capital days have increased from 36.9 days to 70.7 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
127 | 119 | 166 | 130 | 110 | 60 | 71 | 61 | 86 | 194 | 93 | 111 | |
99 | 111 | 139 | 110 | 87 | 63 | 73 | 65 | 67 | 93 | 76 | 95 | |
Operating Profit | 28 | 8 | 28 | 20 | 23 | -4 | -2 | -4 | 20 | 101 | 17 | 16 |
OPM % | 22% | 7% | 17% | 16% | 21% | -6% | -3% | -6% | 23% | 52% | 18% | 14% |
3 | 25 | 4 | 8 | -2 | 4 | 1 | -30 | 0 | -4 | -4 | 1 | |
Interest | 19 | 27 | 24 | 15 | 19 | 10 | 7 | 20 | 26 | 20 | 12 | 5 |
Depreciation | 12 | 9 | 11 | 9 | 10 | 11 | 7 | 8 | 8 | 17 | 14 | 13 |
Profit before tax | 0 | -3 | -3 | 4 | -8 | -20 | -15 | -62 | -14 | 59 | -13 | -1 |
Tax % | 0% | 45% | 31% | -5% | -19% | -5% | -59% | 1% | -29% | 35% | -0% | 182% |
-1 | -5 | -5 | 4 | -7 | -19 | -6 | -63 | -10 | 38 | -13 | -3 | |
EPS in Rs | -0.33 | -3.05 | -2.29 | 1.67 | -2.51 | -6.14 | -1.97 | -21.10 | -4.03 | 13.59 | -4.30 | -0.75 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 9% |
3 Years: | 9% |
TTM: | 19% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 7% |
3 Years: | 19% |
TTM: | 51% |
Stock Price CAGR | |
---|---|
10 Years: | 22% |
5 Years: | 46% |
3 Years: | 20% |
1 Year: | 12% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | -7% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 22 | 22 | 22 | 22 | 22 | 28 | 28 | 29 | 29 | 29 | 31 | 33 |
Reserves | 44 | 30 | 20 | 22 | 16 | 21 | 14 | -43 | -54 | -15 | -3 | 26 |
127 | 164 | 137 | 121 | 126 | 113 | 96 | 141 | 163 | 130 | 75 | 59 | |
96 | 113 | 101 | 77 | 88 | 68 | 77 | 73 | 52 | 42 | 48 | 39 | |
Total Liabilities | 289 | 329 | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 |
93 | 162 | 122 | 104 | 133 | 116 | 108 | 105 | 98 | 94 | 68 | 58 | |
CWIP | 47 | 22 | 27 | 30 | 24 | 28 | 31 | 28 | 26 | 18 | 16 | 23 |
Investments | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
143 | 145 | 130 | 107 | 94 | 85 | 77 | 68 | 66 | 74 | 67 | 76 | |
Total Assets | 289 | 329 | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
11 | 89 | 27 | 12 | 31 | 11 | 27 | 5 | 9 | 79 | 9 | 2 | |
5 | -57 | 37 | 17 | -13 | -3 | -4 | -0 | -0 | -6 | 7 | -9 | |
-13 | -26 | -60 | -30 | -19 | -10 | -23 | 3 | -12 | -63 | -22 | 2 | |
Net Cash Flow | 3 | 6 | 4 | -1 | -0 | -3 | -1 | 9 | -3 | 10 | -5 | -6 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 211 | 209 | 124 | 121 | 97 | 125 | 75 | 48 | 37 | 35 | 79 | 89 |
Inventory Days | 99 | 91 | 77 | 56 | 90 | 139 | 65 | 69 | 41 | 56 | 68 | 78 |
Days Payable | 236 | 363 | 220 | 218 | 266 | 301 | 216 | 192 | 141 | 96 | 91 | 98 |
Cash Conversion Cycle | 73 | -64 | -18 | -41 | -79 | -37 | -75 | -76 | -63 | -5 | 55 | 68 |
Working Capital Days | 96 | -106 | -88 | -75 | -191 | -456 | -181 | -156 | -71 | 6 | 34 | 71 |
ROCE % | 10% | 2% | 10% | 7% | 9% | -8% | -5% | -6% | 10% | 61% | 5% | 4% |
Documents
Announcements
-
Update On The Scheme Of Amalgamation
23 Jul - Company submitted the updation on the NCLT hearing of the Scheme of Amalgamation, as mentioned therein.
-
Updates On Scheme Of Amalgamation
19 Jul - Company enclosed updates about the Scheme of Amalgamation, as mentioned therein.
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 18 Jul
- Publication Of Notice Of 45Th Annual General Meeting Of The Company In The Newspapers. 18 Jul
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
17 Jul - Company enclosed the Reconciliation of Share Capital Audit Report for the quarter ended on 30th June 2024.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
-
Financial Year 2009
from bse
Business Overview:[1]
LLL is a WHO-GMP certified and ISO 9001- certified manufacturer of Pharmaceutical Formulations & Active Pharmaceutical Ingredients across various therapeutic segments, including Lyophilized injections, topical formulations of cream, ointment, foams, gels & lotions.